AstraZeneca

Go or no go? Key FDA decisions for Argenx and Regeneron
Go or no go? Key FDA decisions for Argenx and Regeneron
EP Vantage
FDA
Albireo Pharma
Aldeyra Therapeutics
Alvotech
Amneal Pharmaceuticals
Argenx
ARS Pharmaceuticals
AstraZeneca
Bayer
Bio-Thera Solutions
Biogen
BioMarin Pharmaceutical
Bristol Myers Squibb
Eisai
Eton Pharmaceuticals
F2G
Fabre-Kramer Pharmaceuticals
Fresenius
GSK
Intercept Pharmaceuticals
Ipsen
Ironwood Pharmaceuticals
Merck
Novaliq
Pfizer
Regeneron
Roche
Sanofi
Sarepta Therapeutics
Shionogi
Swedish Orphan Biovitrum
Takeda
Teva Pharmaceutica
UCB Pharma
Flag link:
AstraZeneca reports positive results from endometrial cancer therapy trial
AstraZeneca reports positive results from endometrial cancer therapy trial
Clinical Trials Arena
AstraZeneca
endometrial cancer
clinical trials
Imfinzi
Lynparza
Flag link:
AstraZeneca's drug combo shows positive results in late-stage cancer trial
AstraZeneca's drug combo shows positive results in late-stage cancer trial
Reuters
ASCO 2023
AstraZeneca
Imfinzi
Lynparza
endometrial cancer
Flag link:
AstraZeneca Deepens Gene Editing Capabilities with Revvity Partnership
AstraZeneca Deepens Gene Editing Capabilities with Revvity Partnership
BioSpace
AstraZeneca
Revvity
gene editing
cell therapy
Flag link:
AstraZeneca's Tagrisso, chemo combination shows promise in lung cancer trial
AstraZeneca's Tagrisso, chemo combination shows promise in lung cancer trial
Yahoo/Reuters
AstraZeneca
clinical trials
Tagrisso
Flag link:
AstraZeneca is third member to leave PhRMA in five months
AstraZeneca is third member to leave PhRMA in five months
Stat
AstraZeneca
lobbying
PhRMA
Flag link:
AstraZeneca Expands ADC Portfolio with $600M Deal with LaNova
AstraZeneca Expands ADC Portfolio with $600M Deal with LaNova
BioSpace
AstraZeneca
antibody-drug conjugate
LaNova Medicines
Flag link:
The waxing and waning of the speedy approval
The waxing and waning of the speedy approval
EP Vantage
FDA
drug approvals
accelerated approvals
AbbVie
AstraZeneca
Bayer
Bristol Myers Squibb
JNJ
Merck
Merck KGaA
Novartis
Pfizer
Flag link:
Farxiga’s approval for expanded use highlights potential to differentiate in HF space
Farxiga’s approval for expanded use highlights potential to differentiate in HF space
Clinical Trials Arena
AstraZeneca
Farxiga
heart failure
Flag link:
2023’s biggest launches: the story so far
2023’s biggest launches: the story so far
EP Vantage
drug launches
AbbVie
Almirall
Apellis Pharmaceuticals
Astellas
AstraZeneca
Biogen
CRISPR Therapeutics
Daiichi Sankyo
Eli Lilly
Genmab
GSK
Iveric Bio
Pfizer
Roche
SAGE Therapeutics
Sanofi
Sarepta Therapeutics
Shionogi
Swedish Orphan Biovitrum
Vertex Pharmaceuticals
Flag link:
Sanofi, AstraZeneca Report Promising RSV Pediatric Data Ahead of Pfizer Adcomm
Sanofi, AstraZeneca Report Promising RSV Pediatric Data Ahead of Pfizer Adcomm
BioSpace
Sanofi
AstraZeneca
RSV
antibodies
infants
clinical trials
Flag link:
A blockbuster year could be building
A blockbuster year could be building
EP Vantage
AbbVie
Amgen
AstraZeneca
Bristol Myers Squibb
Daiichi Sankyo
Eli Lilly
Gilead Sciences
Horizon Therapeutics
Merck
Moderna Therapeutics
Novartis
Novo Nordisk
Pfizer
Regeneron
Roche
Sanofi
Flag link:
Farxiga Approval Expands Use to More Patients With Heart Failure
Farxiga Approval Expands Use to More Patients With Heart Failure
eMPR
AstraZeneca
Farxiga
FDA
Flag link:
Biopharma Bets Big on Antibody-Drug Conjugates
Biopharma Bets Big on Antibody-Drug Conjugates
BioSpace
antibody-drug conjugate
Merck
Seagen
M&A
AstraZeneca
BioNTech
Bristol Myers Squibb
Flag link:
AstraZeneca, Pfizer Top 2023 Pharma List for Invention and Innovation
AstraZeneca, Pfizer Top 2023 Pharma List for Invention and Innovation
BioSpace
reputation
AstraZeneca
Pfizer
innovation
IDEA Pharma
Flag link:
AstraZeneca scraps pact with Riva-led Transgene in further blow to oncolytic viruses
AstraZeneca scraps pact with Riva-led Transgene in further blow to oncolytic viruses
Fierce Biotech
AstraZeneca
oncolytic viruses
Transgene
Flag link:
Bristol Myers accuses AstraZeneca of infringing patent on cancer blockbuster Opdivo—again
Bristol Myers accuses AstraZeneca of infringing patent on cancer blockbuster Opdivo—again
Fierce Pharma
Bristol Myers Squibb
Opdivo
patents
legal
AstraZeneca
Flag link:
With negative FDA panel vote, AstraZeneca's Lynparza looks set for narrow nod in prostate cancer
With negative FDA panel vote, AstraZeneca's Lynparza looks set for narrow nod in prostate cancer
Fierce Pharma
AstraZeneca
Merck
Lynparza
metastatic castration-resistant prostate cancer
Flag link:
FDA Questions Efficacy of Merck-AstraZeneca’s Lynparza Ahead of Adcomm
FDA Questions Efficacy of Merck-AstraZeneca’s Lynparza Ahead of Adcomm
BioSpace
Merck
AstraZeneca
FDA
Lynparza
metastatic castration-resistant prostate cancer
Flag link:
AstraZeneca dumps $855M, near-approval rare disease drug after talks with regulators
AstraZeneca dumps $855M, near-approval rare disease drug after talks with regulators
Fierce Biotech
AstraZeneca
clinical trials
ALXN1840
Wilson disease
Flag link:

Pages